News Celgene to file potential MS blockbuster this year Success with ozanimod would justify $7.2 billion outlay for Receptos.
News Valeant's Siliq approved but suicidal thoughts warning will ... But drug will have boxed warning over suicidal ideation.
News Trump demands cuts to 'astronomical' drug prices - but pharm... Trump calls pharma leaders to White House to discuss cutting taxes, regulations - and drug prices
News Delinia adds to Celgene's immunology ambitions Celgene continues with focus on autoimmune diseases.
News Celgene broadens immunology presence with Anokion deal Biotech specialises in autoimmune disorder drugs.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.